VSTM reports VS-7375 cancer-trial response results
The company reports 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease.
The company reports 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease.